Samsara Bio Capital, LLC Atreca, Inc. Transaction History

Samsara Bio Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.88 - $1.22 $231,287 - $320,648	-262,827 Closed	0 $0
Q1 2023 May 15, 2023	BUY	$0.91 - $1.82 $239,172 - $478,345	262,827 New	262,827 $299,000
Q1 2021 May 18, 2021	SELL	$13.0 - $19.34 $1.02 Million - $1.51 Million	-78,108 Reduced 16.45%	396,835 $6.08 Million
Q4 2020 Feb 17, 2021	SELL	$13.03 - $17.09 $1.86 Million - $2.44 Million	-142,617 Reduced 23.09%	474,943 $7.67 Million
Q3 2020 Nov 16, 2020	BUY	$12.67 - $23.19 $1.36 Million - $2.49 Million	107,264 Added 21.02%	617,560 $8.63 Million
Q2 2020 Aug 14, 2020	SELL	$12.52 - $23.45 $1.08 Million - $2.03 Million	-86,542 Reduced 14.5%	510,296 $10.9 Million
Q1 2020 May 15, 2020	BUY	$11.4 - $27.28 $62,358 - $149,221	5,470 Added 0.92%	596,838 $9.88 Million
Q2 2019 Aug 14, 2019	BUY	$17.07 - $18.84 $10.1 Million - $11.1 Million	591,368 New	591,368 $11.1 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.